Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.48 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.45 |
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26554263 | 0.84 | BCHE (0.46) | BCHEBRD4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17830181 | 0.84 | ANO1 (0.47) | BCHEBRD4TP53SMN1; SMN2GAA | |
| SCHEMBL26554307 | 0.84 | BCHE (0.46) | BCHEBRD4MALT1LATS1GAA | |
| SCHEMBL1984198 | 0.82 | BCHE (0.44) | BCHENPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL1984200 | 0.82 | BCHE (0.44) | BCHENPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL23336053 | 0.82 | BCHE (0.44) | BCHEBRD4MALT1LATS1GAA | |
| SCHEMBL25057028 | 0.82 | NPC1 (0.50) | NPC1RAB9ATP53SMN1; SMN2PCSK9 | |
| SCHEMBL29437093 | 0.81 | BCHE (0.46) | BCHEBRD4MALT1LATS1GAA | |
| SCHEMBL29437005 | 0.81 | BCHE (0.51) | BCHEBRD4NPC1RAB9AMALT1 | |
| SCHEMBL26554316 | 0.81 | BCHE (0.51) | BCHEBRD4NPC1RAB9AMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513068-B1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-11 | — | — | EP | disclosed |
| US-8481547-B2 | Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-09 | — | — | US | disclosed |
| EP-2513068-A1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075631-A1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152287-A1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152287-A1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | DPP4, DPP7, DPP3 | BCHE 504/4885BRD4 126/4885NPC1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.